Intra-arterial bevacizumab with blood brain barrier disruption in a glioblastoma xenograft model Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Brain Neoplasms
  • Glioblastoma

abstract

  • In this study we showed a significant survival benefit of repeated IP BV and single IA BV with or without BBBD treated mice compared to single IP BV treated and control mice in a U87 xenograft model.

publication date

  • August 3, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 22946342

Additional Document Info

start page

  • 31

end page

  • 7

volume

  • 10

number

  • 1